Current Edition

news

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-d...
Continue Reading →
news

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gast...
Continue Reading →